Alethio Therapeutics Unveils ATX‑011, a Breakthrough, Mutation‑Agnostic Antibody for Treating Essential Thrombocythemia – a c.$2B Market, and Strengthens Leadership to Accelerate Path to IND
Oxford, UK – 16th April 2026 – Alethio Therapeutics, a biopharmaceutical company developing novel treatments for myeloproliferative neoplasms (MPN), today announced the unveiling of ATX‑011, a first‑in‑class, mutation‑agnostic antibody with potential to disrupt the $2B Essential Thrombocythemia (ET) market. Alongside this, the Company announces the appointment of Steve R. Coats, PhD, a veteran biologics leader, as Chief Development Officer, to advance the ATX-011 programme towards IND submission, targeted for Q1 2027. ATX-011 offers a potent, fast acting, durable solution for ET, a […]
Alethio Therapeutics Launches with New CEO and Chair to Advance Two Targeted Medicines for Myeloproliferative Neoplasms (Chronic Blood Cancers)
Leveraging deep scientific and clinical expertise in MPNs to drive a pipeline of disease-modifying precision therapies that selectively target disease-driving cells Advancing AT-01, a first-in-class ADC programme, with strong preclinical validation towards IND/CTA-enabling studies, expected to begin in the first half of 2026 AT-02 further expands ADC portfolio by targeting mutant CALR, a key MPN […]